

Cover Story
Regulatory News
While breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.
In Brief


Clinical Roundup
Drugs & Targets




Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- USPSTF convenes first meeting in over a year
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality















